

Index

- abdominal ectopic pregnancy, 277
 features, 279
 pathogenesis for, 278
- aberrant tissue bands. *See* amnionic band syndrome
- ABMC. *See* androgenetic biparental mosaicism
- abnormal contour, in placenta, 161–63
 clinical context, 162
 diagnosis for, 163
 features, 162–63
 pathogenesis for, 162
 prognosis for, 163
- abnormal distal villous vascular pattern. *See* distal villous vascular pattern
- abnormal placental location. *See also* ectopic pregnancies
 defined, 275
 placenta previa, 275–76
 clinical context, 275
 features, 275–76
 pathogenesis for, 275
 prognosis for, 276
 risk factors for, 275
 types of, 275
- abruptio placentae
 acute, 70–72
 clinical context, 70
 features, 71, 72
 pathogenesis for, 70–71
 prognosis for, 71–72
- subacute, 75
 clinical context, 75
 features, 74, 75
 pathogenesis, 75
 prognosis for, 75
- ABS. *See* amnionic band syndrome
- acardius acephalus, 252
- accelerated villous maturation (AVM), 62–65
 autoimmune disease and, 62
 clinical context for, 62
 diagnosis of, 64
 features, 62–64
 fetal growth restriction (FGR) and, 62
 fibrinoid necrosis and, 63–64
 IUFD and, 64
 pathogenesis for, 62
 increased fibrin production, 62
 placental mosaicism and, 62
 preeclampsia and, 62
 pregestational diabetes and, 62
 prognosis for, 64
- accessory lobe, 161–63
- active maternal disease processes, 12–14
 clinical context, 12–13
 features of, 13–14
 management options, 13
 noninfectious, 12–13
 pathogenesis for, 13
 prognosis for, 14
- acute abrupcio placentae. *See* abruptio placentae
- acute atherosclerosis. *See* atherosclerosis
- acute myelogenous leukemia (AML), 225
- acute purulent myometritis. *See* purulent myometritis
- acute villitis. *See* villitis
- acute villous edema. *See* villous edema
- ADAM complex. *See* adhesion mutilation complex
- adherent membranes. *See* retained products of conception
- adhesion mutilation (ADAM) complex, 214–16. *See also* amnionic band syndrome
- adrenocortical heterotopia, 231–32
 ancillary diagnostic testing for, 232
 clinical context, 231
 features, 231, 232
 pathogenesis for, 231
 prognosis for, 232
- allantoic duct cyst, 173–76
- AML. *See* acute myelogenous leukemia
- amnion chorion dehiscence, 216–17
- amnion nodosum, 217–19
 ancillary diagnostic testing for, 218
 clinical context, 217
 features, 218
 pathogenesis for, 217–18
 prognosis for, 218–19
 squamous metaplasia, 218, 219
- amnion rupture, late, 216–17
 clinical context, 216
 features, 216–17
 pathogenesis, 216
- amnionic adhesion malformation sequence. *See* amnionic band syndrome
- amnionic band syndrome (ABS), 214–16
 ancillary diagnostic testing for, 215, 216
 clinical context, 214
 features, 215–16
 pathogenesis for, 214–15
 prognosis for, 216
- amniotic fluid infection, 318
- amniotic fluid leakage, 216–17. *See also* amnion rupture
- androgenetic biparental mosaicism (ABMC), with/without hydatidiform mole, 87–90. *See also* placental mesenchymal dysplasia
- aneurysmal pregnancies. *See* early pregnancy loss
- aneuploidies, 16
 parentally inherited, 327
- aneusomy, 23
- angiomyxoma, 174, 175
- anti-phospholipid antibodies, 70, 327–28
- ART. *See* assisted reproductive technology
- arteriopathy. *See* decidual arteriopathy; hypertrophic arteriopathy
- arteriovenous malformations, 173–76
- Asherman syndrome, 284
- aspirin, for active maternal disease processes, 12–13
- assisted reproductive technology (ART), 242, 263, 266, 268–69
- atherosclerosis, acute, 53–55. *See also* decidual arteriopathy
- atretic umbilical artery, 171–73
- atypical implantation site. *See* exaggerated implantation site
- atypical intraplacental hemorrhages. *See* intraplacental hemorrhages
- atypical placental site nodule. *See* placental site nodule
- atypical twinning, 242
- atypical villus morphology, 17–19, 85–87. *See also* dysmorphic villi; early pregnancy loss

- autoimmune disease, 62
- avascular villi, 93, 100. *See also* early pregnancy loss; fetal vascular malperfusion
- AVM. *See* accelerated villous maturation
- B cell leukemia, 224
- Bartter syndrome, 238–39
ancillary diagnostic testing for, 239
clinical context, 238
features, 239
pathogenesis for, 238–39
prognosis for, 239
- basal chronic VUE, 142
- basal intervillous thrombus, 192
- basal plate arteries. *See* persistent muscularization of basal plate arteries
- basal plate microcysts, 51–53. *See also* excessive immature extravillous trophoblast
- basal plate myofibers. *See* myometrial fibers adherent to the basal plate
- basal plate plaque, 195–97
clinical context, 196
differential diagnosis for, 196
features, 196
pathogenesis for, 196
prognosis for, 197
- Beckwith-Wiedemann syndrome, 80, 83, 85
- bilobate placenta, 163–64
clinical context, 163
features, 164
pathogenesis for, 163–64
- bilobed placenta, 161–63
- biparental complete hydatidiform mole, 25
- blighted ovum, 16–17. *See also* early pregnancy loss
- BPMYO. *See* myometrial fibers adherent to the basal plate
- Breus' mole, 73, 188–90. *See also* massive subchorial thrombohematoma
- Candida albicans*, 125, 127
- CAOS. *See* chronic abruption oligohydramnios syndrome
- capillary vessels
abnormalities of fetal vascular malperfusion (FVM)
gross features of, by location, 96
microscopic features, by location, 98–101
villous edema and, 104
- capillary-vascular lesions
chorangiomas, 80–82
clinical context, 80
diagnosis for, 81–82
features, 80–81
pathogenesis for, 80
prognosis for, 82
recurrent pregnancy loss, 329
- chorangiomas. *See also* multifocal chorangiomas
diffuse, 82–83
features, 80–81
pathogenesis for, 80
prognosis for, 82
- multifocal chorangiomas, 82–83
Beckwith-Wiedemann syndrome, 83
clinical context, 82
features, 82–83
pathogenesis for, 82
prognosis for, 83
- villous chorangiosis, 79–80
Beckwith-Wiedemann syndrome and, 80
clinical context, 79
diagnosis of, 80
features, 80
pathogenesis for, 79–80
prognosis for, 80
- central nervous system (CNS) injury, 322–23
chronic villitis and, 323
delayed villous maturation and, 323–24
diffuse villous edema and, 324
etiology of, 322
fetal vascular malperfusion and, 323
histiologic chorioamnionitis, 323
inflammatory processes, 322–23
lesions, 323–24
maternal vascular malperfusion and, 323
meconium effects and, 324
retroplacental hemorrhages and, 324
- centrally hemorrhagic villous infarcts, 66–67, 192–95. *See also* rounded intraplacental hematoma
- cerebral palsy, 112
- cervical ectopic pregnancy, 277
features, 278–79, 280
pathogenesis for, 278
- cervical insufficiency. *See* spontaneous preterm birth
- cesarean scar pregnancy (CSP), 291–92
clinical context, 291
features, 291–92
pathogenesis for, 291
prognosis for, 292
- CHI. *See* histiocytic intervillitis
- chimerism mechanism, 28
- CHM. *See* complete hydatidiform mole
- chorangiomas, 80–82
clinical context, 80
diagnosis for, 81–82
features, 80–81
pathogenesis for, 80
prognosis for, 82
recurrent pregnancy loss, 329
- chorangiomas. *See also* multifocal chorangiomas
diffuse, 82–83
features, 80–81
pathogenesis for, 80
prognosis for, 82
recurrent pregnancy loss, 329
- chorioamnionitis, acute, 70, 71, 123–29
Candida albicans and, 125, 127
chronic, 139, 142
clinical context, 123–24
diagnosis for, 126–27
features, 124–28
fetal response in, 128
funisitis, 124, 125
giant cell villitis and, 123
maternal response in, 127
necrotizing, 125
pathogenesis for, 124
prognosis for, 127–28
obstetric complications, 128
perinatal morbidities, 127–28
silent, 124
stillbirth and, 121
subacute, 129
syphilis and, 123
toxoplasmosis and, 122
umbilical cord and, 121
surface abscesses, 125
- choriocarcinoma, 32–33
ancillary diagnosis of, 33
clinical context for, 32
differential diagnosis of, 33
features of, 32–33
pathogenesis for, 32
prognosis for, 33
in situ or intraplacental, 33–34
clinical context for, 33
differential diagnosis of, 34
features for, 33–34
pathogenesis for, 33
prognosis for, 34
- chorionic cysts, 51–53. *See also* excessive immature extravillous trophoblast
excessive immature extravillous trophoblast and, 51, 52–53
- chorionic villi, 4, 5
abnormalities in, 5
first trimester, 4–5
GCM1, 5
in partial hydatidiform mole, 22
syncytiotrophoblast, 4–5
tertiary, 5
- chorionic villous hemorrhage, 107–8. *See also* intravillous hemorrhage
- chorionicity. *See* dichorionic twins; monochorionic diamniotic twins
- chronic abruption oligohydramnios syndrome (CAOS), 73, 75–76
- chronic chorioamnionitis, 139, 142, 145–47
clinical context, 145
- chorioamnionic rupture sequence. *See* amnionic band syndrome

Index

- chronic chorioamnionitis (cont.)
 diagnosis of, 146
 features, 145–46
 pathogenesis for, 145
 prognosis for, 146–47
 staging of, 146, 147
- chronic deciduitis. *See* deciduitis
- chronic events, for fetal death, 319–20
- chronic histiocytic intervillitis,
 319
- giant chorangioma, 320
- maternal floor infarction, 319
- maternal vascular malperfusion, 319
- mesenchymal dysplasia, 320
- multifocal chorangiomas, 320
- non-infectious chronic villitis, 319
- placental hydrops, 319
- VUE, 319
- chronic histiocytic intervillitis. *See*
 histiocytic intervillitis
- chronic perivasculitis. *See*
 perivasculitis
- chronic villitis, 14, 118–23. *See also*
 villitis of unknown etiology
- clinical context, 118
- CMV and, 119, 120
- diagnosis of, 122
- diffuse, 119
- features, 118–22
- HPV, 123
- HSV and, 120
- with intervillitis, 120
- pathogenesis, 118
- prognosis for, 122–23
- recurrent pregnancy loss, 328
- T. gondii* and, 120–21
- T. pallidum* and, 121–22
- circumvallation, 75–76
- CMV. *See* cytomegalovirus
- CNS injury. *See* central nervous system
 injury
- cocaine abuse, 70
- complete hydatidiform mole, 24–30
- ancillary diagnosis for, 27–28
- with immunohistochemical
 staining, 28
- biparental, 25
- chimerism mechanism, 28
- CHM, 265–66
- clinical context for, 24–25
- with coexistent fetus, 265–66
- ancillary diagnostic testing, 265
- clinical context, 265
- features, 265, 266
- pathogenesis for, 265
- prognosis for, 265–66
- cytotrophoblast, 24
- differential diagnosis for, 27
- features, 25–27, 36
- FIGO 2000 scoring system, 29
- mosaicism mechanism, 28
- pathogenesis of, 25
- pathology of, 24
- prognosis for, 28–30
- syncytiotrophoblast, 24
- with twin gestation, 31–32
- ancillary diagnosis of, 32
- clinical context for, 31
- differential diagnosis of, 32
- features of, 31–32
- pathogenesis for, 31
- villous mesenchyme, 24
- congenital annular bands. *See*
 amniotic band syndrome
- congenital annular effects. *See*
 amniotic band syndrome
- congenital band syndrome. *See*
 amniotic band syndrome
- congenital transverse effects. *See*
 amniotic band syndrome
- constriction rings. *See* amniotic band
 syndrome
- cornual ectopic pregnancy, 277–78
- features, 279
- pathogenesis for, 278
- corticosteroids, for active maternal
 disease processes, 12–13
- CSP. *See* cesarean scar pregnancy
- CTB. *See* cytotrophoblast
- cytomegalovirus (CMV), 119, 120. *See*
also chronic villitis
- cytotrophoblast (CTB)
- invaginations of, 1
- mononuclear, 1
- in placental development, 1–2, 4–5
- as trophoblast stem cell, 1–2
- cytotrophoblasts, 24
- DCH. *See* diffuse chorioamnionic
 hemosiderosis
- decidual arteriopathy, 53–55
- clinical context, 53
- diagnosis for, 55
- features, 54–55
- preeclampsia, 54
- pathogenesis for, 53–54
- prognosis for, 55
- decidual vasculitis, 14
- deciduitis, chronic, 147–49
- clinical context, 147
- features, 148–49
- pathogenesis for, 147–48
- preterm labor, 149
- prognosis for, 149
- dehiscence. *See* uterine rupture
- delayed villous maturation (DVM),
 83–85, 93, 100, 101. *See also*
 fetal vascular malperfusion
- clinical context, 83
- CNS injury and, 323–24
- diagnosis of, 85
- features, 83–85
- pathogenesis, 83
- prognosis for, 85
- delivered placenta, 285–86
- developmentally abnormal early
 pregnancy loss, 10–11
- clinical context for, 10
- defined, 10
- diagnosis and prognosis, 11
- features, 10–11
- pathogenesis for, 10
- developmentally normal early
 pregnancy loss, 11–12
- clinical context, 11
- features of, 11–12
- pathogenesis of, 11
- prognostic implications, 12
- diabetes
- fetal death from, 319–20
- gestational, 83, 193
- pregestational, 62
- pregnancy losses from, 328
- diabetes-associated pregnancy losses,
 328
- diandric uniparental disomy of
 chromosome 11, 25
- dichorionic twins
- fetal growth discordance, 264
- ancillary diagnostic testing, 264
- clinical context, 264
- features, 264
- pathogenesis for, 264
- prognosis for, 264
- placental development, 262–63
- ancillary diagnostic testing for,
 263
- clinical context, 262
- features, 262–63
- mean weights and percentiles for,
 338
- pathogenesis for, 262
- prognosis for, 263
- diffuse chorangiomas, 82–83
- diffuse chorioamnionic hemosiderosis
 (DCH), 73, 75–76
- diffuse chronic villitis, 119
- diffuse distal villous hypoplasia. *See*
 distal villous hypoplasia
- diffuse villitis of unknown etiology
 (VUE), 142. *See also* high grade
 VUE
- diffuse villous edema, 111–12
- clinical context, 111
- features, 111, 112
- pathogenesis for, 111
- prognosis for, 112
- diffuse VUE, 142
- digynic triploidy, 21
- dilation and curettage, 285

- discordant severe IUGR, 264. *See also* fetal growth discordance
- distal villous hypoplasia, 58–60
clinical context, 58
early onset IUGR, 58
defined, 58
diagnosis, 59
features, 59, 60
gross, 59
microscopic, 59
pathogenesis for, 58–59
angiogenic factors, 58
in first trimester, 58
prognosis for, 60
- distal villous immaturity, 83–85. *See also* delayed villous maturation
- distal villous vascular pattern, abnormal, 85–87. *See also* dysmorphic villi
- dizygotic twins, 262
- DVM. *See* delayed villous maturation
- dysmorphic villi, 19, 85–87
Beckwith-Wiedemann syndrome and, 85
clinical context, 85
diagnosis for, 87
early pregnancy loss without, 16–17
clinical context, 16
pathogenesis of, 16
features, 85–87
pathogenesis for, 85
prognosis for, 87
trophoblast inclusions and, 85–87
- early amnion rupture. *See* amnionic band syndrome
- early amnion rupture sequence. *See* amnionic band syndrome
- early pregnancy loss (EPL), with abnormal karyotype
aneuploidies in, 16
defined, 16
with dysmorphic features, 17–19
abnormal vascular patterning, 18
clinical context, 17
features of, 17–19
pathogenesis, 17
prognosis for, 19
without dysmorphic villi, 16–17
clinical context, 16
pathogenesis of, 16
features, 16–17
first trimester chorionic sac, 17
prognosis for, 17
- early pregnancy loss (EPL), with normal karyotype
active maternal disease processes, 12–14
clinical context, 12–13
features of, 13–14
- management options, 13
noninfectious, 12–13
pathogenesis for, 13
prognosis for, 14
- categories of, 9
- chronic histiocytic intervillitis, 13
- decidual vasculitis, 14
defined, 9
- developmentally abnormal, 10–11
clinical context for, 10
defined, 10
diagnosis and prognosis, 11
features, 10–11
pathogenesis for, 10
- developmentally normal, 11–12
clinical context, 11
features of, 11–12
pathogenesis of, 11
prognostic implications, 12
- embryonic, 9
- fetal, 9
- fresh intervillous hemorrhage, 12
guidelines for, 9
first trimester chorionic sac, 9, 10
- lymphoplasmacytic deciduitis, 13
- massive perivillous fibrin deposition, 13
- spontaneous, 11–12
- VUE, 14
- ectopic pregnancies, 276–80
abdominal, 277
features, 279
pathogenesis for, 278
ancillary diagnostic testing for, 279
- cervical, 277
features, 278–79, 280
pathogenesis for, 278
- clinical context, 276
- cornual, 277–78
features, 279
pathogenesis for, 278
- defined, 276
- implantation sites, 277
- ovarian, 277
features, 278–79, 281
pathogenesis for, 278
- prognosis for, 279
- risk factors for, 277
- tubal, 276–77
features, 278, 279, 280
pathogenesis for, 278
- edema. *See also* villous edema
defined, 109
- hydrops placentalis, 109–11
etiology of, 109
features, 109–10
fetal death, 319
pathogenesis for, 109
prognosis for, 109–10
- embryonic early pregnancy loss, 9
- eosinophilic/T cell chorionic vasculitis, 149–50
clinical context, 149
features, 149–50
pathogenesis for, 149
- epithelioid trophoblastic tumor (ETT), 41–43
clinical context for, 41
diagnostic approaches, 42
features of, 41–42
pathogenesis of, 41
prognosis of, 42–43
- EPL. *See* early pregnancy loss
- erythroblastosis fetalis, 208
- E/TCV. *See* eosinophilic/T cell chorionic vasculitis
- ETT. *See* epithelioid trophoblastic tumor
- EVT. *See* extravillous trophoblast
- exaggerated implantation site, 34–36
ancillary diagnosis of, 36
clinical context for, 34
differential diagnosis of, 36
features of, 35–36
MelCam expression, 34, 35
pathogenesis for, 34–35
prognosis for, 36
- excessive immature extravillous trophoblast, 51–53
clinical context for, 51
diagnosis for, 53
features, 51–53
nuclear atypia, 52
pathogenesis for, 51
chorionic cysts, 51, 52–53
membrane microcysts, 53
preeclampsia, 51
prognosis for, 53
- excessive implantation site
trophoblastic giant cells, 49–51.
See also superficial implantation site
- extravillous trophoblast (EVT). *See also* excessive immature extravillous trophoblast
implantation and differentiation of, 2–4
IUGR and, 4
physiologic change, 4
physiologic conversion, 4
regulatory T cells, 4
subtypes, 6–7
terminology, 6–7
- interstitial, 2–4
- mature, 2
- morbidly adherent placenta and, 284–85, 287–89
- superficial implantation site and extravillous trophoblast failure, 49

Index

- extravillous trophoblast (EVT) (cont.)
 invasive extravillous trophoblast, 50
 mature extravillous trophoblast, 50
 transitional, 51–53
- extravillous trophoblastic lineage, 34–43. *See also* placental site trophoblastic tumor
- epithelioid trophoblastic tumor, 41–43
 clinical context for, 41
 diagnostic approaches, 42
 features of, 41–42
 pathogenesis of, 41
- exaggerated implantation site reaction, 34–36
 ancillary diagnosis of, 36
 clinical context for, 34
 differential diagnosis of, 36
 features of, 35–36
 MelCam expression, 34, 35
 pathogenesis for, 34–35
 prognosis for, 36
- placental site nodule, 36–38
 ancillary diagnosis of, 38
 clinical context for, 37
 differential diagnosis of, 37–38
 features of, 37, 38
 pathogenesis of, 37
 prognosis for, 38
- post-cesarean epithelioid trophoblastic lesion, 38–39
 clinical context for, 38
 diagnostic approaches to, 38
 features of, 38
 pathogenesis for, 38
 prognosis of, 39
- fetal death. *See also* chronic events
 acute events for, 317–18
 atraumatic acute placental abruption, 317–18
 spontaneous umbilical cord rupture, 318
 uterine rupture, 317–18
- catastrophic events and, 316–17
 ruptured vasa previa, 317
 traumatic acute placental abruption, 317
 umbilical cord prolapse, 317
- defined, 316
- diabetes-associated, 319–20
- pathologic processes, 316
- subacute events for, 318
 amniotic fluid infection, 318
- fetal maternal hemorrhage, 318
- fetal vascular malperfusion, 318
- fetal early pregnancy loss, 9
- fetal growth discordance
 in dichorionic twins, 264
 ancillary diagnostic testing, 264
 clinical context, 264
 features, 264
 pathogenesis for, 264
 prognosis for, 264
- in monochorionic twins, 253–54
 clinical context, 253
 features, 253–54, 255
 pathogenesis for, 253
 prognosis for, 254
- fetal growth restriction (FGR), 157, 312–14
 features, 313–14
 pathogenesis for, 313
 prognosis for, 314
 risk factors for, 313
- fetal maternal hemorrhage, 318
- fetal membranes, 5–6
- fetal metastatic malignancies, 223–25
 clinical context, 224
 features, 224
- leukemias
 AML, 225
 B cell, 224
 neuroblastomas in, 224
 pathogenesis for, 224
 prognosis for, 225
 transient abnormal myelopoiesis (TAM), 224
- fetal vascular integrity. *See also* edema; hemorrhage
 causes of, 104
 villous edema, 104
- fetal vascular malperfusion (FVM)
 ancillary testing, 94
 grading considerations, 94
 clinical context, 93–94
 fetal/neonatal associations, 94
 predisposed conditions, 93
- CNS injury and, 323
- defined, 93
- fetal death and, 318
- global, 101
- gross features, by location, 94–96
 capillary vessels, 96
 placental muscular vessels, 95–97
 umbilical cord, 94–95, 96
- microscopic features, by location, 96–101
 capillary vessels, 98–101
 placental muscular cells, 96–99
 umbilical cord, 96, 97
- pathogenesis for, 94
- patterns of, 101
- prognosis for, 101
- recurrent pregnancy loss, 329
- segmental, 101
- fetal vascular tears, 105–7
 clinical context, 106
 features, 106–7
 pathogenesis, 106
 prognosis for, 107
 ruptured vasa previa, 106
 stillbirth as result of, 107
 in umbilical cord, 106, 107
- fetal vasculitis, 201
- fetal villous tree development, 4–5
- fetal-stromal vascular developmental abnormalities, 79. *See also specific abnormalities*
- fetoscopic laser occlusion of communicating vessels, 247–49. *See also* laser-treated monochorionic twin placenta
- fetus papyraceus, 266
 clinical context, 266–67
 features, 268
- FGR. *See* fetal growth restriction
- fibrin plaque. *See* subchorionic intervillous thrombus
- fibrinoid necrosis, 49–50, 53–55. *See also* decidual arteriopathy
 accelerated villous maturation and, 63–64
- fibrinoid replacement, 49–50
- FIGO 2000 scoring system, 29
- FIGO/WHO scoring system, 40–41
- first trimester chorionic sac, in early pregnancy loss, 9, 10
 with abnormal karyotype, 17
- first trimester chorionic villi, 4–5
- foam cells, 53–55. *See also* decidual arteriopathy
- focal distal villous hypoplasia. *See* distal villous hypoplasia
- focal placenta accreta, 283
- fragmented placenta. *See* retained products of conception
- fresh intervillous hemorrhage, 12
- FVM. *See* fetal vascular malperfusion
- galactosialidosis, 235, 237
- GBS. *See* Group B streptococci
- GCM1. *See* Glial Cells Missing-1
- gestational diabetes, 83, 193
- gestational trophoblastic disease, 21. *See also* extravillous trophoblastic lineage; villous trophoblastic lineage
- giant cell villitis, 120
 acute chorioamnionitis, 123–24
- giant cells. *See* excessive implantation site trophoblastic giant cells; placental site giant cells
- giant chorangioma, 320
- giant congenital melanocytic nevus (GCMN), 225–26

- ancillary diagnostic testing for, 226
 clinical context, 225
 features, 226
 pathogenesis for, 225–26
 prognosis for, 226
 Glial Cells Missing-1 (GCM1), 5
 global partial fetal vascular malperfusion, 101
 global/partial maternal vascular malperfusion, 62–65. *See also* accelerated villous maturation
 GM 1-gangliosidosis, 235
 Group B streptococci (GBS), 117
- HBV. *See* Hepatitis B virus
 HCA. *See* histologic chorioamnionitis
 HCV. *See* Hepatitis C virus
 HELLP syndrome, 193
 hematogenously spread infections. *See* chronic villitis; villitis
 hematoma. *See also* subchorionic intervillous thrombus
 basal intervillous thrombus, 192
 infarction, 66–67
 clinical context, 66
 features, 67
 multiple, 67
 pathogenesis for, 66–67
 prognosis for, 67
 stillbirth and, 67
 rounded placental, 66–67
 with umbilical cord, 170–71
 hemorrhage. *See also* postpartum hemorrhage
 fetal maternal, 318
 fetal vascular tears, 105–7
 clinical context, 106
 features, 106–7
 pathogenesis, 106
 prognosis for, 107
 ruptured vasa previa, 106
 stillbirth as result of, 107
 in umbilical cord, 106, 107
 intervillous thrombus, 104–5
 clinical context, 104
 features, 104, 105
 pathogenesis for, 104
 prognosis for, 105
 with surrounding villous infarction, 66–67
 intravillous hemorrhage, 107–8
 clinical context, 108
 features, 108
 pathogenesis for, 108
 prognosis for, 108
 products of conception and, 292–93
 clinical context, 292–93
 features, 293
 pathogenesis for, 293
 retroplacental, 324
- heparin, for active maternal disease processes, 12–13
 hepatic heterotopia, 230–31
 ancillary diagnostic testing for, 230
 clinical context, 230
 features, 230, 231
 pathogenesis, 230
 prognosis for, 230–31
 Hepatitis B virus (HBV), 115
 Hepatitis C virus (HCV), 115
 Herpes simplex virus (HSV), 115
 heterotopia
 adrenocortical, 231–32
 ancillary diagnostic testing for, 232
 clinical context, 231
 features, 231, 232
 pathogenesis for, 231
 prognosis for, 232
 hepatic, 230–31
 ancillary diagnostic testing for, 230
 clinical context, 230
 features, 230, 231
 pathogenesis, 230
 prognosis for, 230–31
 high grade VUE, 143
 histiocytic intervillitis, chronic (CHI), 13
 clinical context, 152
 diagnosis for, 153, 154
 features, 153
 fetal death and, 319
 mixed, 153
 pathogenesis for, 152–53
 prognosis for, 153
 recurrent pregnancy loss from, 327, 328
 histologic chorioamnionitis (HCA), 307–8
 CNS injury, 323
 HPV. *See* human papilloma virus
 HSV. *See* Herpes simplex virus
 human papilloma virus (HPV), 123
 hyaline membrane disease, 112
 hyalinized villi. *See* early pregnancy loss
 hydatidiform mole. *See* androgenetic biparental mosaic chimerism; complete hydatidiform mole; partial hydatidiform mole
 hydropic phenotype, 26–27
 hydropic villi. *See* early pregnancy loss
 hydrops placentalis, 109–11
 etiology of, 109
 features, 109–10
 fetal death, 319
 pathogenesis for, 109
 prognosis for, 109–10
 hypercoiled umbilical cord, 169–70
 hyperprostaglandin E syndrome, 239
 hypertension, maternal, 70, 193
 hypertrophic arteriopathy, 53–55. *See also* decidual arteriopathy
 hypocoiled umbilical cord, 169–70
 hypoplastic umbilical artery, 171–73
 hysterectomy
 after placenta delivery, 286, 287
 for PSTT, 39
 specimen with placenta in situ, 286–87, 288, 289
 with uterine atony, 299
 uterine rupture and, 297
- I cell disease, 235
 ICM. *See* inner cell mass
 idiopathic chronic inflammatory lesions, 308–9
 in vitro fertilization (IVF), 266, 268–69
 increased circulating fetal nucleated red blood cells (NRBCs)
 clinical context for, 206
 diagnosis for, 208–11
 ancillary testing in, 211
 differential, 208–11
 erythroid precursors, 210
 features, 207–8
 normoblastemia and, 207–8
 causes of, 209
 dyserythropoietic, 208
 erythroblastosis fetalis and, 208
 stem vessel, 207
 types of, 210–11
 umbilical cord, 207
 pathogenesis, 206–7
 prognosis for, 211
 relative to absolute, translation formulas for, 206
 threshold values for, 210
 indicated preterm birth (IPB), 307
 infant sialic acid storage disorder, 235
 infarction-hematoma, 66–67, 192–95.
See also rounded intraplacental hematoma
 clinical context, 66
 features, 67
 multiple, 67
 pathogenesis for, 66–67
 prognosis for, 67
 stillbirth and, 67
 inner cell mass (ICM), 1
 intermediate trophoblast, increased immature, 51–53. *See also* excessive immature extravillous trophoblast
 interstitial extravillous trophoblast, 2–4
 intervillitis
 chronic histiocytic, 13
 clinical context, 129

Index

- intervillositis (cont.)
 diagnosis, 130
 features, 129–30
 prognosis for, 130
 VUE with, 120
- intervillous fibrin, increased, 62–65, 130–31. *See also* accelerated villous maturation
- intervillous thrombus (IVT), 104–5.
See also subchorionic intervillous thrombus
 clinical context, 104
 features, 104, 105
 pathogenesis for, 104
 prognosis for, 105
 with surrounding villous infarction, 66–67
- intrafunicular hemorrhage, 170–71
- intramural fibrin deposition, 93. *See also* fetal vascular malperfusion
- intramural lipid laden macrophages, 53–55. *See also* decidual arteriopathy
- intraplacental choriocarcinoma, 33–34
 clinical context for, 33
 differential diagnosis of, 34
 features for, 33–34
 pathogenesis for, 33
 prognosis for, 34
- intraplacental hemorrhages, atypical
 basal intervillous thrombus, 192
 basal plate plaque, 195–97
 clinical context, 196
 differential diagnosis for, 196
 features, 196
 pathogenesis for, 196
 prognosis for, 197
- massive subchorial thrombohematoma, 188–90
 clinical context, 188
 defined, 188
 diagnosis of, 189–90
 features, 189
 pathogenesis, 188–89
 prognosis for, 190
- rounded intraplacental hematoma, 192–95
 clinical context for, 193
 differential diagnosis for, 194–95
 features, 193–94
 lesions and, 194
 pathogenesis for, 193
 prognosis for, 195
- subchorionic intervillous thrombus, 190–92
 clinical context, 191
 differential diagnosis of, 192
 features, 191
 pathogenesis, 191
 prognosis for, 192
- intraplacental trophoblast islands, 6
- intrauterine fetal death (IUFD), 64
- intrauterine growth restriction (IUGR), 4, 137, 193
 discordant severe, 264
 early onset, 58
 fetal growth restriction, 157, 312–14
 features, 313–14
 pathogenesis for, 313
 prognosis for, 314
 risk factors for, 313
- intravillous hemorrhage, 107–8
 clinical context, 108
 features, 108
 pathogenesis for, 108
 prognosis for, 108
- invasive hydatidiform mole, 30–31
 ancillary diagnosis of, 30
 clinical context for, 30
 differential diagnosis of, 30
 features of, 30
 prognosis of, 30–31
- IPB. *See* indicated preterm birth
- irregular placental contour, 161–63
- irregular villous contour, 17–19, 85–87. *See also* dysmorphic villi; early pregnancy loss
- isthmocele pregnancy. *See* cesarean scar pregnancy
- IUFD. *See* intrauterine fetal death
- IUGR. *See* intrauterine growth restriction
- IVF. *See* in vitro fertilization
- IVH. *See* intravillous hemorrhage
- IVT. *See* intervillous thrombus
- labor. *See* preterm labor; spontaneous preterm birth
- large for gestational age (LGA) placenta, 157, 158, 159
- laser ablation. *See* laser-treated monochorionic twin placenta
- laser-treated monochorionic twin placenta, 247–49
 ancillary diagnostic testing for, 248–49
 clinical context, 247–48
 features, 248, 249
 prognosis for, 249
- late amnion rupture. *See* amnion rupture
- leiomyomas, implantation over, 70
- lesions, inflammatory. *See also* capillary-vascular lesions
 chronic chorioamnionitis, 139, 142, 145–47
 clinical context, 145
 diagnosis of, 146
 features, 145–46
 pathogenesis for, 145
- prognosis for, 146–47
 staging of, 146, 147
- chronic deciduitis, 147–49
 clinical context, 147
 features, 148–49
 pathogenesis for, 147–48
 preterm labor, 149
 prognosis for, 149
- in CNS injury, 323–24
- eosinophilic/T cell chorionic vasculitis, 149–50
 clinical context, 149
 features, 149–50
 pathogenesis for, 149
- in placental infections, 307–9
 acute marginal abruption, 308
 chronic abruption, 308
 histologic chorioamnionitis, 307–8
 idiopathic chronic, 308–9
 maternal vascular malperfusion, 308
- rounded intraplacental hematoma and, 194
- umbilical cord, 173–76
 clinical context, 173
 features, 174–75
 pathogenesis for, 173–74
 prognosis for, 176
- leukemia, 222
 AML, 225
 B cell, 224
- LGA placenta. *See* large for gestational age placenta
- Listeria monocytogenes*, 117–18
- long umbilical cord, 167–68
- lymphomas, 222
 non-Hodgkin lymphoma, 222
- lymphoplasmacytic deciduitis, 13, 147–49. *See also* deciduitis
- lysosomal storage disease (LSD), 235–38
 ancillary diagnostic testing, 236–37
 clinical context, 235
 features, 235–36
 pathogenesis for, 235
 prognosis for, 237
 specific disorders, 235
- MAP. *See* morbidly adherent placenta
- marginal abruption
 acute, 72–75
 clinical context, 72
 diffuse chorioamnionic hemosiderosis and, 73, 75–76
 features, 73
 pathogenesis for, 73
 prognosis for, 73
 chronic, 75–76
 clinical context, 75

- features, 75–76
 - pathogenesis for, 75
 - prognosis for, 76
- massive perivillous fibrin deposition (MPFD), 13, 130–31, 181–84
 - ancillary testing for, 183
 - clinical context, 181
 - features, 182–83
 - fetal death and, 319
 - pathogenesis for, 181–82
 - prognosis for, 183–84
- massive subchorial thrombohematoma, 188–90
 - clinical context, 188
 - defined, 188
 - diagnosis of, 189–90
 - ancillary testing in, 190
 - differential, 189–90
 - features, 189
 - pathogenesis, 188–89
 - prognosis for, 190
- maternal floor infarct (MFI), 130–31, 181–84
 - ancillary testing for, 183
 - clinical context, 181
 - features, 182–83
 - fetal death and, 319
 - pathogenesis for, 181–82
 - prognosis for, 183–84
 - recurrent pregnancy loss and, 328
- maternal hypertension. *See* hypertension
- maternal metastatic malignancies, 220–25
 - ancillary diagnostic testing for, 223
 - breast cancer, 222, 223
 - cervical cancer, 223
 - clinical context, 220
 - features, 220–21
 - hematological, 222
 - lung cancer, 222–23
 - lymphomas, 222
 - melanomas, 221–22
 - non-Hodgkin lymphoma, 222
 - pathogenesis, 220
 - prognosis for, 223
- maternal vascular abnormalities, 49–78. *See also specific abnormalities*
- maternal vascular integrity, 70. *See also* abruptio placentae; marginal abruption
- maternal vascular malperfusion (MVM), 308, 319. *See also* accelerated villous maturation; villous infarcts
 - CNS injury, 323
 - complete/segmental, 65–66
 - global/partial, 62–65
 - infarction-hematoma, 66–67
 - clinical context, 66
 - features, 67
 - multiple, 67
 - pathogenesis for, 66–67
 - prognosis for, 67
 - stillbirth and, 67
 - recurrent pregnancy loss and, 328
 - villous infarcts, remote and recent, 65–66
 - clinical context, 65
 - features of, 65–66
 - multiple, 65
 - pathogenesis for, 65
 - prognosis for, 66
- maturation defect, 83–85. *See also* delayed villous maturation
- mature extravillous trophoblast, 2
- MC. *See* multifocal chorangiomas
- meconium effects
 - clinical context, 199
 - CNS injury and, 324
 - decidual, 202
 - defined, 199
 - diagnosis for, 202–3
 - ancillary testing in, 203
 - differential, 202–3
 - discharge-to-delivery intervals, 204
 - features, 199–200, 201
 - particulate, 201
 - pathogenesis for, 199
 - prognosis for, 203–4
 - risk factors, 200
 - superficial, 202
 - Wharton's jelly and, 203
- meconium myonecrosis, 200–2
 - features, 203
 - fetal vasculitis, 201
 - normoblastemia, 201–2
 - reactive amnion hyperplasia, 201
- MelCam protein molecule, 34, 35
- membrane rupture. *See* amnionic band syndrome
- membranous microcysts, 51–53. *See also* excessive immature extravillous trophoblast
 - excessive immature extravillous trophoblast and, 53
- mesenchymal dysplasia, 320
- metastatic malignancies, 220–25. *See also* fetal metastatic malignancies; maternal metastatic malignancies
- metastatic tumors, 220. *See also* fetal metastatic malignancies; maternal metastatic malignancies; *specific malignancies*
- MFI. *See* maternal floor infarct
- microcysts. *See* basal plate microcysts; membranous microcysts
- microinfarcts, 62–65. *See also* accelerated villous maturation
- mineralization. *See* villous trophoblast basement membrane
- mixed chronic histiocytic intervillitis, 153
- molar pregnancy. *See* complete hydatidiform mole; partial hydatidiform mole
- monoamniotic placentation, twinning and
 - clinical context, 254–57
 - features, 255–56
 - umbilical cord entanglement, 256
 - incidence rates for, 255
 - pathogenesis for, 255
 - prognosis for, 256
 - twin anemia-polycythemia sequence (TAPS) and, 255
 - twin reversed arterial perfusion (TRAP) syndrome and, 255
 - twin-to-twin transfusion syndrome (TTTS) and, 254–55
- monochorionic diamniotic twins. *See also* laser-treated monochorionic twin placenta; twin anemia-polycythemia sequence; twin reversed arterial perfusion syndrome; twin-to-twin transfusion syndrome
 - fetal growth discordance, 253–54
 - clinical context, 253
 - features, 253–54, 255
 - pathogenesis for, 253
 - prognosis for, 254
 - monozygotic twinning, 242
 - pathogenesis for, 241–42
 - placental development, 241–44
 - ancillary diagnostic testing for, 244
 - atypical twinning, 242
 - chorionicity and, 241
 - clinical context for, 241
 - features, 242–44
 - prognosis for, 244
 - monochorionic twins. *See* fetal growth discordance
 - mononuclear CTBs (cytotrophoblast), 1
 - monozygotic twinning, 242
 - monozygotic twins, 262
 - morbidly adherent placenta (MAP). *See also* placenta accreta Asherman syndrome and, 284
 - clinical context, 283–84
 - complications of, 284
 - defined, 283
 - diagnosis for, 284
 - ancillary testing in, 289

Index

- morbidly adherent placenta (cont.)
 extravillous trophoblast and,
 284–85, 287–89
 features, 285–89
 delivered placenta, 285–86
 dilation and curettage, 285
 hysterectomy after placenta
 delivery, 286, 287
 hysterectomy specimen with
 placenta in situ, 286–87, 288,
 289
 pathogenesis for, 284–85
 pathologic staging of, 283
 placenta accreta and, 283–89
 prognosis for, 289
 mosaicism mechanism, 28
 mucopolidosis type I, 235
 mucopolidosis type II, 235
 multifocal chorangiomas (MC),
 82–83
 Beckwith-Wiedemann syndrome, 83
 clinical context, 82
 features, 82–83
 fetal death and, 320
 pathogenesis for, 82
 prognosis for, 83
 multifocal low-grade VUE, 139
 multilobed placenta, 161–63
 multiple gestations. *See* dichorionic
 twins; monozygotic twins; triplet
 pregnancies
 mural hypertrophy, 53–55. *See also*
 decidual arteriopathy
 MVM. *See* maternal vascular
 malperfusion
 myometrial fibers adherent to the basal
 plate (BPMYO), 290–91
 clinical context for, 290
 features, 290, 291
 prognosis for, 290–91
 necrotizing acute chorioamnionitis,
 125
 necrotizing funisitis, 124, 125
 neuroblastomas, 224
 nodular/stunted embryos, 16–17. *See*
also early pregnancy loss
 non-Hodgkin lymphoma, 222
 noninfectious active maternal disease
 processes, 12–13
 non-infectious chronic villitis, 319
 nonspecific trophoblast hyperplasia.
See trophoblast hyperplasia
 normoblastemia
 meconium myonecrosis and, 201–2
 mild, 210
 moderate, 210–11
 NRBCs and, 207–8
 causes of, 209
 dyserythropoietic, 208
 erythroblastosis fetalis and, 208
 stem vessel, 207
 types of, 210–11
 umbilical cord, 207
 severe, 210–11
 NRBCs. *See* increased circulating fetal
 nucleated red blood cells
 nuclear atypia, 52
 obliterative villitis, 119
 occult placenta accreta. *See* myometrial
 fibers adherent to the basal plate
 oligohydramnios, 70
 omphalomesenteric duct cyst, 173–76
 ovarian ectopic pregnancy, 277
 features, 278–79, 281
 pathogenesis for, 278
 parentally inherited aneuploidy, 327
 partial hydatidiform mole, 21–24
 ancillary diagnosis for, 23–24
 clinical context for, 21
 differential diagnosis for, 22–23
 features of, 21–22, 23
 pathogenesis of, 21
 prognosis for, 24
 triploidy and, 21
 partial placenta accreta, 283
 parvovirus, 131
 patchy villous edema, 112
 features, 112
 prognosis for, 112
 patchy VUE, 138
 perivasculitis, chronic, 53–55. *See also*
 decidual arteriopathy
 periventricular leukomalacia, 247
 perivillous fibrin deposition, 141. *See*
also maternal floor infarct
 localized (perivillous fibrin plaque),
 184–85
 clinical context, 184
 features, 184, 185
 pathogenesis for, 184
 MPFD, 13, 130–31, 181–84
 ancillary testing for, 183
 clinical context, 181
 features, 182–83, 201
 fetal death and, 319
 pathogenesis for, 181–82
 prognosis for, 183–84
 perivillous fibrin plaque (PFP). *See*
 perivillous fibrin deposition
 persistent muscularization of basal
 plate arteries, 49–51. *See also*
 superficial implantation site
 persistent right umbilical vein, 171–73
 PFP. *See* perivillous fibrin deposition
 placenta, development of, 1–2. *See also*
 abnormal placental location;
 dichorionic twins; fetal
 metastatic malignancies;
 maternal metastatic
 malignancies; monozygotic
 diamniotic twins; small for
 gestational age
 abnormal contours in, 161–63
 clinical context, 162
 diagnosis for, 163
 features, 162–63
 pathogenesis for, 162
 prognosis for, 163
 abnormalities in, 159–61
 clinical context, 159
 features, 160–61
 pathogenesis for, 159–60
 prognosis for, 161
 bilobate placenta, 163–64
 clinical context, 163
 features, 164
 pathogenesis for, 163–64
 chorionic villi, 4, 5
 abnormalities in, 5
 first trimester, 4–5
 GCM1, 5
 syncytiotrophoblast, 4–5
 tertiary, 5
 chorionicity and, 241
 CTB (cytotrophoblast), 1–2, 4–5
 EVT (extravillous trophoblast) and,
 implantation and
 differentiation of, 2–4
 IUGR and, 4
 physiologic change, 4
 physiologic conversion, 4
 regulatory T cells, 4
 subtypes, 6–7
 terminology, 6–7
 fetal membranes, 5–6
 fetal villous tree development, 4–5
 fetal-placental weight, by gestational
 age, 337, 342–43
 gross examination of, 333–35
 ICM (inner cell mass), 1
 intraplacental trophoblast islands, 6
 knowledge gaps for, 7
 LGA, 157, 158, 159
 shape of, 161–64
 size in, 157–61
 abnormalities in, 159–61
 standard deviation for placental
 weights, 336, 342–43
 stillbirth by time interval, 341
 TE (trophoblast) cells, 1
 vascular integrity in, 70
 placenta accreta, 283–89
 placenta membranacea, 163–64
 clinical context, 163
 features, 164
 pathogenesis for, 163–64

- placenta previa, 275–76
 clinical context, 275
 features, 275–76
 pathogenesis for, 275
 prognosis for, 276
 risk factors for, 275
- placental abruption, atraumatic acute, 317–18
- placental attachment disorders. *See specific disorders*
- placental bed vascular subinvolution. *See subinvolution of placental site*
- placental hemangiomas, 80–82. *See also chorangiomas*
- placental hydrops. *See hydrops placentalis*
- placental infections, 115. *See also specific infections*
 silent, 131
- placental mesenchymal dysplasia (PMD), 87–90
 clinical context, 87
 diagnosis, 89, 90
 features, 88–89
 pathogenesis for, 87–88
 prognosis for, 90
- placental mosaicism, 62
- placental muscular vessels, with fetal vascular malperfusion
 gross features, by location, 95–97
 microscopic features, by location, 96–99
- placental site giant cells, increase in, 49–51. *See also superficial implantation site*
- placental site nodule, 36–38
 ancillary diagnosis of, 38
 clinical context for, 37
 differential diagnosis of, 37–38
 features of, 37, 38
 pathogenesis of, 37
 prognosis for, 38
- placental site trophoblastic tumor (PSTT), 39–41
 clinical context for, 39
 diagnostic approaches to, 40
 features for, 39–40
 FIGO/WHO scoring system for, 40–41
 hysterectomy for, 39
 pathogenesis for, 39
 prognosis for, 40–41
- placental teratomas. *See teratomas*
- placental vascular anomaly with diffuse mesenchymal stem villous hyperplasia, 87–90. *See also placental mesenchymal dysplasia*
- plaque. *See basal plate plaque*
- plasma cell deciduitis, 139
- PMD. *See placental mesenchymal dysplasia*
- poorly vascularized villi. *See early pregnancy loss*
- post-cesarean epithelioid trophoblastic lesion, 38–39
 clinical context for, 38
 diagnostic approaches to, 38
 features of, 38
 pathogenesis for, 38
 prognosis of, 39
- postpartum hemorrhage (PPH)
 defined, 299
 etiologies of, 300
 incidence rates for, 299
 retained placenta, 301–2
 clinical context for, 301
 features, 301
 pathogenesis for, 301
 prognosis for, 302
 subinvolution of placental site, 302–4
 clinical context, 302
 diagnostic testing for, 304
 features, 303–4
 hysterectomy with, 302
 pathogenesis for, 302
 uterine atony, 299–301
 clinical context, 299
 features, 299
 hysterectomy with, 299
 pathogenesis for, 299
 prognosis for, 301
- PPROM. *See preterm premature rupture of the membranes*
- preeclampsia, 51, 54, 62, 193
- premature labor. *See spontaneous preterm birth*
- preterm labor, 149, 193
- preterm premature rupture of the membranes (PPROM), 70
- progesterone, for active maternal disease processes, 12–13
- proximal-distal villous discordance, 85–87. *See also dysmorphic villi*
- pseudocysts, 173–76
- pseudo-partial mole, 87–90. *See also placental mesenchymal dysplasia*
- PSTT. *See placental site trophoblastic tumor*
- purulent myometritis, acute, 131
- reactive amnion hyperplasia, 201
- recent villous infarcts. *See villous infarcts*
- recurrent multiple chorangioma syndrome, 80–82. *See also chorangiomas*
- recurrent pregnancy loss
 anatomic disorders, 327
 abnormal uterine anatomy, 327, 328–29
 cervical incompetence, 327
 diabetes-associated, 328
 in early pregnancy, chronic histiocytic intervillitis, 328–29
 from immunologic disorders, 327–28
 antiphospholipid antibodies, 327–28
 chronic histiocytic intervillitis, 327
 in late pregnancy, 328–29
 chronic histiocytic intervillitis, 328
 chronic villitis, 328
 fetal vascular malperfusion and, 329
 maternal floor infarction, 328
 maternal vascular malperfusion and, 328
 multiple chorangioma syndrome and, 329
 parentally inherited aneuploidy, 327
 regulatory T cells, 4
 villitis of unknown etiology (VUE) and, 137, 139
- remote villous infarcts. *See villous infarcts*
- retained placenta, 301–2
 clinical context for, 301
 features, 301
 pathogenesis for, 301
 prognosis for, 302
- retained products of conception (POC), 292–93
 clinical context, 292–93
 features, 293
 pathogenesis for, 293
- retroplacental hemorrhage, 324
- rounded intraplacental hematoma, 192–95
 clinical context for, 193
 differential diagnosis for, 194–95
 features, 193–94
 lesions and, 194
 pathogenesis for, 193
 prognosis for, 195
- rounded placental hematoma, 66–67. *See also infarction-hematoma*
- ruptured vasa previa, 106, 317
- Salla disease, 235
- segmental/complete fetal vascular malperfusion, 101
- segmental/complete maternal vascular malperfusion, 65–66. *See also villous infarcts*

Index

- SGA. *See* small for gestational age
shallow implantation site, 49–51. *See also* superficial implantation site
short umbilical cord, 167–68
sialidosis, 235
silent chorioamnionitis, 124
single umbilical artery (SUA), 171–73
 clinical context, 172
 features, 173
 pathogenesis for, 172–73
 prognosis for, 173
small for gestational age (SGA)
 clinical context, 312–13
 defined, 312
 placental development
 clinical context for, 157–58
 diagnosis for, 159
 features, 158–59
 fetal growth restriction and, 157
 pathogenesis for, 158
 prognosis for, 159
smooth muscle cells within basal plate.
 See myometrial fibers adherent to the basal plate
SPB. *See* spontaneous preterm birth
spontaneous early pregnancy loss, 11–12
spontaneous preterm birth (SPB), 307
 risk factors for, 307
squamous metaplasia, 218, 219
stem cells, trophoblastic (TSC), 1–2
stem vessel normoblastemia, 207
stem vessel obliteration, 93, 99. *See also* fetal vascular malperfusion
stem villous vascular obliteration, 139–41
stillbirth, 67
 acute chorioamnionitis and, 121
 from fetal vascular tears, 107
 in triplet pregnancies, 270
Streeter dysplasia, 214–16. *See also* amniotic band syndrome
streptococci. *See* Group B streptococci
stromal nuclear karyomegaly, 17–19.
 See also early pregnancy loss
stromal-architectural abnormalities.
 See also dysmorphic villi
 delayed villous maturation, 83–85
 clinical context, 83
 CNS injury and, 323–24
 diagnosis of, 85
 features, 83–85
 pathogenesis, 83
 prognosis for, 85
 placental mesenchymal dysplasia, 87–90
 clinical context, 87
 diagnosis, 89, 90
 features, 88–89
 pathogenesis for, 87–88
 prognosis for, 90
SUA. *See* single umbilical artery
subamniotic dissection of vernix caseosa, 216–17. *See also* amnion rupture
subchorial tuberos hematoma, 188–90. *See also* massive subchorial thrombohematoma
subchorionic intervillous thrombus, 190–92
 clinical context, 191
 differential diagnosis of, 192
 features, 191
 pathogenesis, 191
 prognosis for, 192
subinvolution of placental site, 302–4
 clinical context, 302
 diagnostic testing for, 304
 features, 303–4
 hysterectomy with, 302
 pathogenesis for, 302
succenturiate lobe, 161–63
superficial implantation site, 49–51
 clinical context for, 49
 diagnosis for, 50–51
 extravillous trophoblast and
 failure of, 49
 invasive, 50
 mature, 50
 features for, 49–50
 fibrinoid necrosis, 49–50
 fibrinoid replacement, 49–50
 vascular smooth muscle, 50
 pathogenesis for, 49
 prognosis for, 51
surface epithelial inclusion cyst, 173–76
syncytial knots, 62–65. *See also* accelerated villous maturation
syncytiotrophoblast, 4–5, 24
syphilis, 123
T cells. *See* eosinophilic/T cell chorionic vasculitis; regulatory T cells
T. gondii, 120–21
T. pallidum, 121–22
TAM. *See* transient abnormal myelopoiesis
TAPS. *See* twin anemia-polycythemia sequence
TE cells. *See* trophoctoderm cells
Tenney-Parker change, 62–65. *See also* accelerated villous maturation
teratomas, placental, 232–33
 clinical context for, 232
 features, 232–33
 pathogenesis for, 232
 prognosis for, 233
tertiary chorionic villi, 5
thrombi. *See* basal intervillous thrombus; subchorionic intervillous thrombus
thrombosis, 93. *See also* fetal vascular malperfusion
thyroid disease, 70
tobacco use, 70
TOPS. *See* twin oligohydramnios-polyhydramnios sequence
total placenta accreta, 283
toxoplasmosis, 122
transient abnormal myelopoiesis (TAM), 224
transitional extravillous trophoblast, 51–53. *See also* excessive immature extravillous trophoblast
TRAP. *See* twin reversed arterial perfusion syndrome
trauma, 70
triplet pregnancies, 268–70
 clinical context, 268–69
 clinical features, 269–70
 patterns of, 269
 prognostic implications, 270
 stillborns in, 270
triploidy, 21
trophoctoderm (TE) cells, 1
trophoblast hyperplasia, nonspecific, 17–19, 85–87. *See also* dysmorphic villi; early pregnancy loss
trophoblast inclusions, 17–19. *See also* early pregnancy loss
 dysmorphic villi and, 85–87
trophoblast islands, 51–53. *See also* excessive immature extravillous trophoblast
trophoblast stem cells (TSC), 1–2. *See also* extravillous trophoblast
trophoblastic developmental abnormalities, 49–57. *See also* specific abnormalities
TSC. *See* trophoblast stem cells
TTTS. *See* twin-to-twin transfusion syndrome
tubal ectopic pregnancy, 276–77
 features, 278, 279, 280
 pathogenesis for, 278
tumors. *See* specific tumors
Turner syndrome, 232
twin anemia-polycythemia sequence (TAPS), 241, 249–51
 ancillary diagnostic testing, 251
 clinical context, 249–50
 features, 250–51
 monoamniotic placentation and, 255
 pathogenesis for, 250
 prognosis for, 251

- twin birth weight discordance, 264. *See also* fetal growth discordance
- twin gestation, complete hydatidiform mole with, 31–32
- ancillary diagnosis of, 32
- clinical context for, 31
- differential diagnosis of, 32
- features of, 31–32
- pathogenesis for, 31
- twin oligohydramnios-polyhydramnios sequence (TOPS), 245–47, 249. *See also* twin-to-twin transfusion syndrome
- twin reversed arterial perfusion (TRAP) syndrome, 241, 251–53
- acardius acephalus, 252
- ancillary diagnostic testing, 253
- clinical context, 251–52
- features, 252–53, 254
- monoamniotic placentation and, 255
- pathogenesis for, 252
- prognosis for, 253
- twins. *See also* dichorionic twins; fetal growth discordance; monoamniotic placentation; monochorionic diamniotic twins
- atypical, 242
- dizygotic, 262
- monozygotic, 242, 262
- twin-to-twin transfusion syndrome (TTTS), 241, 245–47
- ancillary diagnostic testing, 246–47
- clinical context, 245
- staging in, 245
- features, 246, 247
- laser-treated, 247–49
- laser-treated monochorionic twin placenta, 247–49
- ancillary diagnostic testing for, 248–49
- clinical context, 247–48
- features, 248, 249
- prognosis for, 249
- monoamniotic placentation and, 254–55
- pathogenesis for, 245
- periventricular leukomalacia and, 247
- prognosis for, 247
- type 1 vasa previa, 164–66
- type 2 vasa previa, 161–63
- type 3 vasa previa, 164–66
- umbilical cord
- with acute chorioamnionitis, 121
- surface abscesses, 125
- avulsion of, 170–71
- coiling abnormalities, 169–70
- clinical context, 169
- features, 169–70
- pathogenesis for, 169
- prognosis for, 170
- cord coil index, 340
- cystic and solid lesions, 173–76
- clinical context, 173
- features, 174–75
- pathogenesis for, 173–74
- prognosis for, 176
- developmental abnormalities with, 164–76
- fetal death and, from spontaneous rupture, 318
- with fetal vascular malperfusion
- gross features, by location, 94–95, 96
- microscopic features, by location, 96, 97
- fetal vascular tears in, 106, 107
- by gestational age, 339
- hematoma with, 170–71
- insertion site abnormalities, 164–66
- clinical context, 165–66
- defined, 164–65
- features, 166
- furcate, 165
- pathogenesis for, 166
- peripheral, 165
- prognosis for, 166
- length and thickness abnormalities, 167–68
- clinical context, 167
- features, 167–68
- pathogenesis for, 167
- prognosis for, 168
- loss of integrity, 170–71
- clinical context, 170–71
- surface alterations, 170
- monoamniotic placentation and, 256
- non-membranous, 165, 166
- NRBCs and, 207
- prolapse, 317
- ruptured artery aneurysm, 170–71
- single umbilical artery (SUA), 171–73
- clinical context, 172
- features, 173
- pathogenesis for, 172–73
- prognosis for, 173
- type 2 vasa previa, 164–66
- type 3 vasa previa, 164–66
- Wharton's jelly and, 167–68, 171
- uterine atony, 299–301
- clinical context, 299
- features, 299
- hysterectomy with, 299
- pathogenesis for, 299
- prognosis for, 301
- uterine rupture, 296–98
- ancillary diagnostic testing, 297
- clinical context, 296
- features, 297
- fetal death from, 317–18
- hysterectomy and, 297
- pathogenesis for, 296–97
- prognosis for, 297–98
- risk factors for, 296
- vacuolation of villous trophoblast, 235–38. *See also* lysosomal storage disease
- amniotic, 238
- idiopathic, 237
- immature, 238
- vanishing twin syndrome, 266–68
- clinical context, 266–67
- features, 267–68
- fetus papyraceus, 266
- clinical context, 266–67
- features, 268
- pathogenesis for, 267
- prognosis for, 268
- variable maturation, 83–85. *See also* delayed villous maturation
- vascular ectasia, 93, 96. *See also* fetal vascular malperfusion
- vascular smooth muscle, 50
- villitis, 115. *See also* chronic villitis
- acute, 116–18
- clinical context, 116
- diagnosis, 117–18
- features, 116–17
- GBS, 117
- Listeria monocytogenes*, 117–18
- prognosis, 118
- CNS injury and, 323
- features, 115
- giant cell, 120, 123–24
- HBV and, 115
- HCV and, 115
- HSV and, 115
- obliterative, 119
- villitis of unknown etiology (VUE). *See also* lesions
- chronic chorioamnionitis and, 139, 142
- clinical context, 137
- common findings with, 139–41
- diagnosis of
- ancillary testing in, 143
- differential, 141–43
- diffuse, 142
- eosinophilic/T cell chorionic vasculitis and, 139
- features, 138, 139, 140
- fetal death and, 319
- grading of, 138–39
- high grade, 143

Index

- villitis of unknown etiology (cont.)
 IUGR and, 137
 multifocal low-grade, 139
 patchy, 138
 pathogenesis for, 137–38
 regulatory T cell subtypes, 137
 perivillous fibrin deposition and, 141
 pitfalls of, 141–43
 plasma cell deciduitis and, 139
 prognosis for, 143
 stem villous vascular obliteration
 and, 139–41
 subtypes, 138, 140, 141
 basal chronic, 142
 villous agglutination and infarction
 and, 141
- villous agglutination, 62–65. *See also*
 accelerated villous maturation
- villous agglutination and infarction, 141
- villous chorangiosis, 79–80
 Beckwith-Wiedemann syndrome
 and, 80
 clinical context, 79
 diagnosis of, 80
 features, 80
 pathogenesis for, 79–80
 prognosis for, 80
- villous cistern formation, 19. *See also*
 early pregnancy loss
- villous dysmaturity, 83–85. *See also*
 delayed villous maturation
- villous edema
 chronic, 109–11
 diffuse, 111–12
 clinical context, 111
 CNS injury and, 324
 features, 111, 112
 pathogenesis for, 111
 prognosis for, 112
 patchy, 112
 features, 112
 prognosis for, 112
- villous hydrops, 109–11. *See also*
 hydrops placentalis
- villous infarcts
 centrally hemorrhagic, 66–67
 intervillous thrombus with, 66–67
 remote and recent, 65–66
 clinical context, 65
 features of, 65–66
 multiple, 65
 pathogenesis for, 65
 prognosis for, 66
- villous mesenchyme, 24
- villous paucity, 62–65. *See also*
 accelerated villous maturation
- villous stromal cells, 18. *See also* early
 pregnancy loss
- villous stromal hemorrhage,
 107–8. *See also* intravillous
 hemorrhage
- villous stromal-vascular karyorrhexis,
 93, 100. *See also* fetal vascular
 malperfusion
- villous trophoblast basement
 membrane, mineralization of,
 238–39. *See also* Bartter
 syndrome
- villous trophoblastic lineage, 21–34.
See also choriocarcinoma;
 complete hydatidiform mole
 diandric uniparental disomy of
 chromosome 11, 25
 hydropic phenotype, 26–27
 invasive hydatidiform mole,
 30–31
 ancillary diagnosis of, 30
 clinical context for, 30
 differential diagnosis of, 30
 features of, 30
 prognosis of, 30–31
 partial hydatidiform mole, 21–24
 ancillary diagnosis for, 23–24
 clinical context for, 21
 differential diagnosis for, 22–23
 features of, 21–22, 23
 pathogenesis of, 21
 prognosis for, 24
 triploidy and, 21
 vitelline hemangioma, 173–76
 VUE. *See* villitis of unknown etiology
- Wharton's jelly, 167–68, 171, 203
- yolk sac tumor, 233
 clinical context, 233
 features, 233
 pathogenesis for, 233
- zygosity. *See* dichorionic twins;
 monochorionic diamniotic
 twins